Role of type II topoisomerase mutations and AcrAB efflux pump in fluoroquinolone-resistant clinical isolates of Proteus mirabilis

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 3, 2006, Pages 673-677

  Saito, Ryoichi ^a,b   Sato, Kenya ^b   Kumita, Wakako ^b   Inami, Natsuko ^b   Nishiyama, Hiroyuki ^b   Okamura, Noboru ^b   Moriya, Kyoji ^a   Koike, Kazuhiko ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

DNA gyrase; P. mirabilis; Topoisomerase IV

Indexed keywords

AMINO ACID; AMPICILLIN; BACTERIAL PROTEIN; CEFTAZIDIME; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; DNA TOPOISOMERASE IV; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MINOCYCLINE; PROTEIN PARC; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; DNA SEQUENCE; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROTEUS MIRABILIS; URINARY TRACT INFECTION; WILD TYPE;

ANTI-BACTERIAL AGENTS; BASE SEQUENCE; DNA GYRASE; DNA TOPOISOMERASES, TYPE II, BACTERIAL; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; GENES, BACTERIAL; HUMANS; MEMBRANE TRANSPORT PROTEINS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MUTATION; PROTEUS INFECTIONS; PROTEUS MIRABILIS; URINARY TRACT INFECTIONS;

EID: 33747892583     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl297     Document Type: Article

References (14)

1. Rozalski A, Sidorczyk Z, Kotelko K. Potential virulence factors of Proteus bacilli. Microbiol Mol Biol Rev 1997; 61: 65-89.
2. de Champs C, Bonnet R, Sirot D et al. Clinical relevance of Proteus mirabilis in hospital patients: A two year survey. J Antimicrob Chemother 2000; 45: 537-9.
3. Hernandez JR, Martinez-Martinez L, Pascual A et al. Trends in the susceptibilities of Proteus mirabilis isolates to quinolones. J Antimicrob Chemother 2000; 45: 407-8.
4. Hooper DC. Mechanisms of fluoroquinolone resistance. Drug Resist Updat 1999; 2: 38-55.
5. Weigel LM, Anderson GJ, Tenover FC. DNA gyrase and topoisomerase IV mutations associated with fluoroquinolone resistance in Proteus mirabilis. Antimicrob Agents Chemother 2002; 46: 2582-7.
6. Oethinger M, Kem WV, Jellen-Ritter AS et al. Ineffectiveness of topoisomerase mutations in mediating clinically significant fluoroquinolone resistance in Escherichia coli in the absence of the AcrAB efflux pump. Antimicrob Agents Chemother 2000; 44: 10-3.
7. Jellen-Ritter AS, Kern WV. Enhanced expression of the multidrug efflux pumps AcrAB and AcrEF associated with insertion element transposition in Escherichia coli mutants selected with a fluoroquinolone. Antimicrob Agents Chemother 2001; 45: 1467-72.
8. Baucheron S, Imberechts H, Chaslus-Dancla E et al. The AcrB multidrug transporter plays a major role in high-level fluoroquinolone resistance in Salmonella enterica serovar Typhimurium phage type DT204. Microb Drug Resist 2002; 8: 281-9.
9. Olliver A, Valle M, Chaslus-Dancla E et al. Role of an acrR mutation in multidrug resistance of in vitro-selected fluoroquinolone-resistant mutants of Salmonella enterica serovar Typhimurium. FEMS Microbiol Lett 2004; 238: 267-72.
10. Ge B, McDermott PF, White DG et al. Role of efflux pumps and topoisomerase mutations in fluoroquinolone resistance in Campylobacter jejuni and Campylobacter coli. Antimicrob Agents Chemother 2005; 49: 3347-54.
11. Visalli MA, Murphy E, Projan SJ et al. AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis. Antimicrob Agents Chemother 2003; 47: 665-9.
12. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard M7-A6. NCCLS, Wayne, PA, USA, 2003.
13. Vila J, Ruiz J, Marco F et al. Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and MICs. Antimicrob Agents Chemother 1994; 38: 2477-9.
14. Vila J, Ruiz J, Goni P et al. Detection of mutations in parC in quinolone-resistant clinical isolates of Escherichia coli. Antimicrob Agents Chemother 1996; 40: 491-3.